Andere Sprachen NeuroPace, Inc.

Aktien

A3CM06

US6412881053

NPCE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
6,47 ^USD	-1,22 %		-6,37 %	-37,25 %

13.05.	NEUROPACE, INC. : Morgan Stanley bekräftigt seine neutrale Bewertung	ZM
08.05.	NeuroPace, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

NeuroPace to Participate in Two Healthcare Conferences in May	14.05.
NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M	08.05.
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update	08.05.
NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024	08.05.
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024	17.04.
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference	27.03.
North American Morning Briefing : Inflation -2-	15.03.
NeuroPace Shares Decline Following Q4 Financial Results	06.03.
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M	05.03.
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million	05.03.
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024	05.03.
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	15.02.
NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary	07.02.
NeuroPace Preliminary Q4 Revenue Beats Street View; Shares Rise	08.01.
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates	08.01.
NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023	08.01.
NeuroPace, Inc. Revises Revenue Guidance for the Full Year 2023	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NeuroPace, Inc.

Aktien

A3CM06

US6412881053

NPCE

Andere Sprachen

Filter